The other guy said was a sell due to the change in direction of management spending money on research and development to apply the product to other diseases rather than focusing on growing market share and cash flows from Scenesse. a fair comment but biotechs also need to focus on future cash flows and expansion of products - unfortunately Clinuvel haven't got the logical mindset to do both.
Hard to see a cap raise when holding $160m in cash, and growing (but could be grown faster - why not on the Australia PBS?
Who in the company is responsible for expansion of markets for Scenesse - which relies on Govts to approve and insurers to support?). Where the CEO gets involved in all and sundry, why is there no COO employed to drive the existing business?
Overpaid and under-delivering. Patsy board. AGM coming up 31 October.
The other guy said was a sell due to the change in direction of...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.86 |
Change
0.000(0.00%) |
Mkt cap ! $744.5M | |||
| Open | High | Low | Value | Volume |
| $14.93 | $15.07 | $14.76 | $684.2K | 45.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 550 | $14.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.99 | 219 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$14.95 |
Change
0.000 ( 0.36 %) |
||||
| Open | High | Low | Volume | ||
| $14.96 | $15.07 | $14.77 | 2565 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| CUV (ASX) Chart |